Friday, 6 November 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 7, 2026

Robinhood Markets and Starbucks have been highlighted as Zacks Bull and Bear of the Day

View original at finance.yahoo.com
Robinhood Markets and Starbucks have been highlighted as Zacks Bull and Bear of the Day For Immediate Release Chicago, IL – January 7, 2026 – Zacks Equity Research shares Robinhood Markets HOOD, as the Bull of the Day and Starbucks SBUX as the Bear of the Day…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Q4 was a milestone quarter in getting 'Back to Starbucks', having delivered global comp growth for the first time in seven quarters. This continues to be a multi-year turnaround. The company remains focused on driving topline while managing costs to deliver durable, sustainable growth and long-term shareholder value.

    80% confidence
  • The revised net sales guidance reflects a broad-based recovery in most of Microchip's end markets, driven by improving inventory conditions at distributors as well as direct customers. The company saw strong bookings in December and expects further improvement in the March quarter.

    80% confidence
  • The top 5% of all stocks receive the highly coveted Zacks Rank #1 (Strong Buy). These stocks should outperform the market more than any other rank.

    80% confidence
  • Starbucks has Zacks Rank #5 (Strong Sell) due to analysts taking earnings expectations lower

    80% confidence
  • Robinhood Markets sports the highly-coveted Zacks Rank #1 (Strong Buy), with its EPS outlook remaining rosy

    80% confidence
  • Since 2000, top stock-picking strategies have blown away the S&P's +7.7% average gain per year with average gains of +48.4%, +50.2% and +56.7% per year

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com